Table 2 Patient characteristics of development set and validation set
| Â | Development set | Validation set | P value |
|---|---|---|---|
n | 108 | 46 | Â |
Age | 64 (41–81) | 65 (54–83) | 0.62 |
Sex/male (%) | 75 (69) | 33 (72) | 0.926 |
FEV1 (L) | 1.54 (0.45–3.1) | 1.63 (0.63–2.9) | 0.424 |
FEV1%pred | 58.12 (15.8–99.5) | 62.38 (30.1–110.6) | 0.263 |
FVC (L) | 2.79 (0.98–5.21) | 2.82 (0.92–4.75) | 0.852 |
FVC% pred | 80.14 (34.4–119.6) | 82.72 (49.2–123.8) | 0.671 |
FEV1/FVC | 54.00 (31–68.59) | 57.16 (32–68.98) | 0.082 |
RV (L) | 4.12 (1.97–7.31) | 3.90 (1.34–6.43) | 0.608 |
TLC (L) | 6.55 (3.88–9.84) | 6.14 (3.52–8.72) | 0.316 |
RV/TLC (%) | 75.58 (39–242.4) | 68.53 (31–149.2) | 0.522 |
BMI (kg/m2) | 24.10 (11.3–37.3) | 23.48 (17.2–30) | 0.357 |
FFMI (kg/m2) | 17.09 (9.5–23.8) | 16.78 (11.8–19.3) | 0.461 |
Height (cm) | 165.42 (141–180) | 165.40 (147–177) | 0.991 |
Weight (Kg) | 65.84 (26.7–110.4) | 63.26 (40.2–90.3) | 0.323 |
mMRC | 2 (0–4) | 2 (0–4) | 0.599 |
CAT | 15 (0–37) | 14 (0–36) | 0.804 |
RFthick (cm) | 5.48 (4.51–6.97) | 5.41 (4.5–6.96) | 0.515 |
RFcsa (cm2) | 7.06 (6.01–8.22) | 7.03 (6.06–8.28) | 0.78 |
6MWD (m) | 370.8 (108–554) | 365.9 (177–510) | 0.721 |
QMS (kg) | 42.89 (21.55–68.1) | 42.94 (24.2–65.05) | 0.986 |